Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 125,960

Document Document Title
WO/2017/132752A1
A loxapine film oral dosage form includes loxapine salt, free base, or prodrug in an amount effective to provide relief from acute agitation associated with schizophrenia or bipolar 1 disorder via oral transmucosal delivery, dispersed in...  
WO/2017/135462A1
The purpose of the present invention is to provide a novel compound having TRPA1 antagonist activity, a medicine containing the compound, and a pharmaceutical agent applicable to prophylaxis or treatment of diseases associated with TRPA1...  
WO/2017/133681A1
The present application relates to a compound represented by formula (III) or a pharmaceutically acceptable salt, solvent compound, active metabolite, crystal polymorph, ester, isomer, or prodrug thereof. The application further provides...  
WO/2017/133517A1
Disclosed are a phosphamide derivative, a method for manufacturing the same, and uses thereof Particularly disclosed are a compound shown by general formula (I) as well as a pharmaceutically acceptable salt or stereisomer (I) thereof, wh...  
WO/2017/134038A1
The present invention relates to a brexpiprazole dihydrate crystalline form having a particle size distribution of d50 of at most 10 µm and less than 5% w/w of brexpiprazole anhydrate. The present invention also relates to a process for...  
WO/2017/133714A1
An application of a fullerene structure in the preparation of medications for treating Parkinson's disease. The fullerene structure comprises at least one of the following active ingredient groups: a fullerene, a metallofullerene, and a ...  
WO/2017/133337A1
The present invention provides a substituted benzimidazolone compound and a composition comprising the same. The present invention discloses a substituted benzimidazolone compound represented by formula (I) and a pharmaceutical compositi...  
WO/2017/136375A1
This invention relates to deuterated forms of morpholinobenzo[d]thiazol-2-yl)-4-methylpiperidine-1-carboxa mide compounds, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of ...  
WO/2017/135399A1
A compound having TrkA inhibitory activity, or a pharmaceutically permissible salt thereof are provided. This invention relates to a compound represented by formula (I) or a pharmaceutically permissible salt thereof, and to a pharmaceuti...  
WO/2017/133990A1
The present invention relates to compounds of formula I wherein R1' is CH3; R1 is CH3, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1' and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, CH3, ethyl, isopro...  
WO/2017/134280A1
The present invention relates to combinations and methods for the treatment of neurological disorders related Amyloid beta toxicity and/or neuronal death. More specifically, the present invention relates to novel combinatorial therapies ...  
WO/2017/133518A1
An application using an icariin and an icariin derivative, a pharmaceutically acceptable salt thereof, an Epimedium flavonoid comprising the icariin or the icariin derivative, and an Epimedium extract comprising the icariin or the icarii...  
WO/2017/134468A1
The invention relates to a novel salt of cytisine and pharmaceutical compositions comprising that salt. In particular, the invention relates to a succinate salt of cytisine which displays improved excipient compatibility, permitting the ...  
WO/2017/133634A1
The present invention relates to an opioid receptor antagonist conjugate and a use thereof. In particular, the present invention relates to a covalent coupling conjugate of a hydrophilic polymer and an opioid receptor antagonist and the ...  
WO/2017/136376A1
The present invention relates to compositions and methods for the delivery of agents to a subject, particularly to the central nervous system (CNS).  
WO/2017/136834A1
The presently disclosed subject matter provides for in vitro methods of inducing differentiation of human stem cells into neural crest, cranial placode or non-neuro ectoderm precursors, and cells generated by such methods. The presently ...  
WO/2017/133258A1
Disclosed in is a 1H-indazole derivative as shown in formula (A), and also disclosed is a method for preparing the compound and the use thereof as an IDO inhibitor. The compound of the present invention can be used for preventing and/or ...  
WO/2017/131097A1
Provided is a pharmaceutical composition for the treatment or prevention of a cognitive disease or disorder, the composition comprising a compound represented by formula (1), an enantiomer thereof or diasteriomer thereof, or a pharmaceut...  
WO/2017/130638A1
Provided is a material effective for improving the activity of nerves in the brain or for preventing or remedying brain dysfunction. Disclosed is an agent for activating astrocyte glucose metabolism comprising, as an active ingredient, a...  
WO/2017/131601A1
The invention relates to a molecule enabling removal of neurotoxicity observed in neuron cells due to various reasons.  
WO/2017/128291A1
Provided is an application of berberine in preparing a pharmaceutical to prevent and/or treat Alzheimer's disease. Berberine can reduce the protein levels of Aβ, APP, phosphorylated tau422, and phosphorylated tau396, and can improve the...  
WO/2017/130190A1
This invention provides a novel formulation for effective delivery of a pharmaceutically active ingredient such as a peptide possessing neuroprotective activity. Also provided are methods for treating pertinent clinical implications such...  
WO/2017/131149A1
A compound shown by general formula (I-1) (in the formula, all symbols are as stated in the specification.) has selective S1P5 receptor-binding activity. Adjusting this activity makes it possible to obtain a therapeutic agent for S1P5-me...  
WO/2017/131156A1
The purpose of the present invention is to provide a novel compound having antagonist activity against retinoid-related orphan receptor γ, and exhibiting a therapeutic effect or a preventive effect for an autoimmune disease such as mult...  
WO/2017/132155A1
The invention provides methods of treating schizophrenia in a subject, including for example, administering to the subject an agent that inhibits expression or activity of a C4A polynucleotide or polypeptide. The invention also provides ...  
WO/2017/129139A1
Provided in the present invention are a sulfamic acid ester as an indoleamine-2,3-dioxygenase inhibitor, a preparation method therefor and a use thereof. The structure of the inhibitor in the present invention is shown in general structu...  
WO/2017/129829A1
The present invention relates to compounds that are antagonists of the orexin-1 receptor. The compounds have the structural formula (I) defined herein. The present invention also relates to processes for the preparation of these compound...  
WO/2017/130108A1
The present invention relates to a formulation for use in treating migraine aura comprising, as active ingredients, an extract of Tanacethum parthenium, magnesium cations, 5-hydroxy-tryptophan. The present invention further relates to a ...  
WO/2017/129782A1
The present invention relates to highly soluble, non-fluorescent and photostable myosin inhibitors; especially, for in vivo inhibition of the ATPase activity of neuronal non-muscle myosin 2 of formula (II): wherein Q1, Q2, Q3, Q4, R1, R2...  
WO/2017/130859A1
A neuronal cell death inhibitor having as an active ingredient a bacterium belonging to Bifidobacterium longum, such as Bifidobacterium longum subspecies infantis LMG 23728 or Bifidobacterium longum subspecies longum ATCC 15707, or a cul...  
WO/2017/132432A8
Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutica...  
WO/2017/131171A1
Provided is a compound represented by general formula (I) and a pharmaceutically acceptable salt thereof. [In formula (I): A1 is a methylene group, and the like; A2 is a methylene group or an oxygen atom; A3 is an azetidinyl group, pyrro...  
WO/2017/132432A1
Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical...  
WO/2017/129061A1
Disclosed is an application of substituted cinnamamide derivatives in the preparation of Anti-anxiety medications, the substituted cinnammide derivatives are compounds having the structure of formula (I) or pharmaceutically acceptable sa...  
WO/2017/129987A1
Compositions comprising a nutritionally or pharmaceutically effective dosage of an extract of Salvia officinalis and an acceptable carrier are provided. The compositions show particular potential in the treatment of age-related pathologi...  
WO/2017/130933A1
The purpose of the present invention is to provide a therapeutic agent for neurodegenerative diseases, more specifically to provide a neuroprotective therapeutic agent, for example, a novel therapeutic agent for ophthalmic neurodegenerat...  
WO/2017/132675A1
This disclosure relates to method for treating Sanfilippo Syndrome B (also Mucopolysaccharidosis III B, MPSIIIB) by enzyme replacement therapy.  
WO/2017/129046A1
Provided in the present invention are a compound of polyethylene glycol and opioid as shown in general formula (I), and a pharmaceutical composition comprising the compound. By means of covalently bonding a plurality of opioids on a deri...  
WO/2017/132127A1
This invention addresses tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73), ANAVEX1-41 and/or Anavex19-144 in a method of treatment for neurodevelopmental disorders. Particular reference...  
WO/2017/124835A1
The present invention discloses a compound (I) having 1-sulfonamido-4-aryloxy as a basic backbone. A preliminary activity test showed that the compound of the present invention provides excellent interference of a binding of NRF2 by KEAP...  
WO/2017/125919A1
The present invention provides a composition comprising a synergistic combination of melatonin, valerenic acid and carnosic acid. The composition may be used in the treatment and prevention of several different disorders including inflam...  
WO/2017/125841A1
The present invention relates to pharmaceutical compositions of Teriflunomide or pharmaceutically acceptable salts thereof and method of preparation of such compositions. Typically, the composition according to present invention comprise...  
WO/2017/126700A1
Provided are a pharmaceutical composition containing a VNUT inhibitor and a method using a VNUT inhibitor, each of which can be employed for treating or preventing a disease or condition selected from the group consisting of non-alcoholi...  
WO/2017/124970A1
Provided are a dicaffeoyl-spermidine derivative glycoside, a preparation method therefor and a use. Biological activity tests show that the dicaffeoyl-spermidine derivative glycoside has antioxidant activity and antiviral activity, the a...  
WO/2017/126645A1
The purpose of the present invention is to provide a composition for inhibiting the migration of endotoxin into blood. According to the present invention, a composition for inhibiting the migration of endotoxin into blood is provided, wh...  
WO/2017/126648A1
A therapeutic method whereby it becomes possible to reduce adverse side effects and the QOL of a patient can be improved while exerting a therapeutic effect on pain has been demanded. When N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-...  
WO/2017/125065A1
Use of an algal proteoglycan extract and a composition comprising the same in the manufacture of a medicament for treating or preventing tumor, pain, inflammation or diseases mediated by inflammatory factors.  
WO/2017/124969A1
Provided are a dicaffeoyl-spermidine cyclic derivative and a use. Biological activity tests show that the dicaffeoyl-spermidine cyclic derivative has anti-senile dementia activity and antioxidant activity, the activity of the derivative ...  
WO/2017/125932A1
The present invention is directed to indoline derivatives and salts thereof, compositions comprising them and uses thereof for the treatment of diseases and disorders associated with at least one of oxidative stress, an immune response, ...  
WO/2017/127417A1
The invention relates to phosphopantothenate compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel compounds of the invention.  

Matches 201 - 250 out of 125,960